胃癌手术后替吉奥单药口服化疗的临床疗效

目的:观察可手术的胃癌患者术后替吉奥单药的临床应用及其效果。方法:以临床分期Ⅱ期及Ⅲ期胃癌患者，并经手术治疗后获得痊愈者为入选对象，术后1个月试验组给予替吉奥胶囊口服，用量为80mg/（m2·d）,早晚分次口服，d1-14。对照组给于FOLFOX4标准方案，每2周作为一个周期，3周期后评价疗效。结果:试验组与对照组比较:在不良反应发生率、KPS评分级别、临床获益率、有效率、患者手术后2年生存率均无明显统计学差异。结论:胃癌手术后应用替吉奥单药控制，不良反应轻微，术后2年生存率与对照组相比无统计学差异，治疗依从性较好，值得推广应用。

Clinical research of gastric cancer patients treated with single S-1 after operation

Objective:To observe clinical application and results of patients with operable gastric cancer treated with S-1 monotherapy.Methods:Clinical stage Ⅱ and Ⅲ patients with gastric cancer，and after surgery to get healed were selected as objects，the test group was given S-1 after one month，with dosage of 80mg/(m2·d)，divided doses in morning and night，day 1-14 medication；Control group was given standard regimen:FOLFOX4，every two weeks as a period.Finally，two groups were evaluated after 3 cycles.Results:In two groups,incidence of adverse reactions，KPS score level，clinical benefit rate，efficient rate，2-year survival rate of patients after surgery，were no significant statistical difference.Conclusion:For gastric cancer patients after surgery with S-1 single drug treatment，adverse reactions are mild，and there were no significant difference between the test group and the control group on 2-year survival rate,and treatment compliance.